fluorouracil has been researched along with Amenorrhea in 53 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Amenorrhea: Absence of menstruation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated QOL data from 874 pre- and perimenopausal women with lymph node-negative breast cancer who were randomly assigned to receive six courses of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy, ovarian suppression with goserelin for 24 months, or six courses of classical CMF followed by 18 months of goserelin." | 9.12 | Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. ( Aebi, S; Bernhard, J; Castiglione-Gertsch, M; Coates, AS; Collins, J; Forbes, JF; Gelber, RD; Goldhirsch, A; Hürny, C; Murray, E; Price, KN; Thürlimann, B; Zahrieh, D, 2007) |
| "The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 9.10 | Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). ( Blake, GM; Blamey, R; Fogelman, I; Palmer, M; Sauerbrei, W; Schumacher, M; Serin, D; Stewart, A; Wilpshaar, W, 2003) |
| "5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node metastases (Ludwig Breast Cancer Study I)." | 9.05 | A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. ( , 1985) |
| "This is a follow-up study of 226 premenopausal women with breast cancer who had received one of three chemotherapy regimens: conventional (cyclophosphamide/methotrexate/5-fluorouracil), anthracycline based, and anthracycline-taxane based." | 7.77 | Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. ( Alavi, N; Bahrami, A; Djavid, GE; Heidari, K; Mehrdad, N; Najafi, M; Najafi, S; Olfatbakhsh, A; Rajaii, E, 2011) |
| "The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3." | 7.71 | Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. ( Blamey, R; Cuzick, J; de Haes, JC; de Matteis, A; Eiermann, W; Fogelman, I; Geberth, M; Jonat, W; Kaufmann, M; Lisboa, B; Namer, M; Palmer, M; Sauerbrei, W; Schumacher, M; Stewart, A; Szakolczai, I, 2002) |
| "The effect of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or tamoxifen treatment on endocrine function was investigated in premenopausal and postmenopausal breast cancer patients." | 7.68 | Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. ( Balar, DB; Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Trivedi, SN; Vora, HH, 1992) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) and tamoxifen (TM) on hypothalamic-pituitary-ovarian function was studied in 120 women with stage I-II operable breast cancer." | 7.67 | Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. ( Citarella, F; Contegiacomo, A; d'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Iaffaioli, RV; Marinelli, A; Pagliarulo, C, 1986) |
| "In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes." | 6.72 | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006) |
| "In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone." | 6.71 | Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ( Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Nasi, ML; O'Neill, A; Price, KN, 2003) |
| "Tamoxifen use was a significant predictor for CIA (P = 0." | 5.36 | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. ( Chen, L; Dai, JC; Ling, LJ; Liu, XA; Ma, JJ; Tao, AD; Wang, S; Yin, H; Zha, XM; Zhou, WB, 2010) |
| "In a multi-centre, randomised, controlled study, 1016 premenopausal women received seven series of FEC (F: fluorouracil, E: epirubicin and C: cyclophosphamide) for early stage breast cancer." | 5.14 | The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. ( Ahlgren, J; Andersen, J; Andersson, M; Bergh, J; Bjerre, K; Blomquist, C; Lidbrink, E; Lindman, H; Mouridsen, H; Rosendahl, M, 2009) |
| "We evaluated QOL data from 874 pre- and perimenopausal women with lymph node-negative breast cancer who were randomly assigned to receive six courses of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy, ovarian suppression with goserelin for 24 months, or six courses of classical CMF followed by 18 months of goserelin." | 5.12 | Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. ( Aebi, S; Bernhard, J; Castiglione-Gertsch, M; Coates, AS; Collins, J; Forbes, JF; Gelber, RD; Goldhirsch, A; Hürny, C; Murray, E; Price, KN; Thürlimann, B; Zahrieh, D, 2007) |
| "The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.10 | Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). ( Blake, GM; Blamey, R; Fogelman, I; Palmer, M; Sauerbrei, W; Schumacher, M; Serin, D; Stewart, A; Wilpshaar, W, 2003) |
| "The relation between tumour oestrogen and progesterone receptor status, menstrual status, relapse-free survival, and overall survival was analysed in 411 patients with early breast cancer randomised to receive either postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) or no additional treatment (control)." | 5.06 | Mechanism of action of adjuvant chemotherapy in early breast cancer. ( Howell, A; Padmanabhan, N; Rubens, RD, 1986) |
| "5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node metastases (Ludwig Breast Cancer Study I)." | 5.05 | A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. ( , 1985) |
| "The sera of 15 premenopausal women with operable breast cancer and who had developed amenorrhea during adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil were analyzed for the following hormones: 17-beta-estradiol, luteinizing hormone, thyroid stimulating hormone and prolactin." | 5.04 | Hormonal study in patients developing amenorrhea during adjuvant chemotherapy for breast cancer. ( Recchione, C; Rossi, A, 1979) |
| "To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980." | 4.82 | 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. ( Bonadonna, G; Daidone, MG; Gianni, L; Moliterni, A; Pilotti, S; Valagussa, P; Zambetti, M, 2005) |
| "This is a follow-up study of 226 premenopausal women with breast cancer who had received one of three chemotherapy regimens: conventional (cyclophosphamide/methotrexate/5-fluorouracil), anthracycline based, and anthracycline-taxane based." | 3.77 | Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. ( Alavi, N; Bahrami, A; Djavid, GE; Heidari, K; Mehrdad, N; Najafi, M; Najafi, S; Olfatbakhsh, A; Rajaii, E, 2011) |
| "We studied the incidence and duration of amenorrhea induced by two chemotherapy regimens: (i) 6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2 on day 1 every 3 weeks (6FEC) and (ii) 3 cycles of FEC 100 followed by 3 cycles of docetaxel 100 mg/m2 on day 1 every 3 weeks (3FEC/3D)." | 3.74 | Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. ( Berliere, M; Dalenc, F; Donnez, J; Kerger, J; Machiels, JP; Malingret, N; Piette, P; Roche, H; Symann, M; Vindevogel, A, 2008) |
| "The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3." | 3.71 | Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. ( Blamey, R; Cuzick, J; de Haes, JC; de Matteis, A; Eiermann, W; Fogelman, I; Geberth, M; Jonat, W; Kaufmann, M; Lisboa, B; Namer, M; Palmer, M; Sauerbrei, W; Schumacher, M; Stewart, A; Szakolczai, I, 2002) |
| "An increasing number of women is treated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy for breast cancer." | 3.70 | Alterations in laboratory test results during adjuvant breast cancer treatment. ( Ahokoski, O; Irjala, K; Kailajärvi, M; Salminen, E; Virtanen, A, 2000) |
| "147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens." | 3.68 | Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients. ( Addamo, GF; Coialbu, T; Costantini, M; Giacchero, A; Guido, T; Repetto, L; Rosso, R; Toma, S, 1992) |
| "The effect of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or tamoxifen treatment on endocrine function was investigated in premenopausal and postmenopausal breast cancer patients." | 3.68 | Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. ( Balar, DB; Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Trivedi, SN; Vora, HH, 1992) |
| "Adjuvant chemotherapy with cyclophosphamide, 5-fluorouracil and methotrexate (CMF)-induced permanent ovarian suppression in 47 of 77 (61%) premenopausal patients with axillary node positive breast cancer." | 3.67 | Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. ( Beex, LV; Benraad, TJ; Kloppenborg, PW; Mackenzie, MA; Raemaekers, JM; Smals, AG, 1988) |
| "The effect of cyclophosphamide, methotrexate and fluorouracil (CMF) on ovarian function has been studied in 74 pre-menopausal patients with operable breast cancer." | 3.67 | Ovarian function and adjuvant chemotherapy for early breast cancer. ( Moore, JW; Padmanabhan, N; Rubens, RD; Wang, DY, 1987) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) and tamoxifen (TM) on hypothalamic-pituitary-ovarian function was studied in 120 women with stage I-II operable breast cancer." | 3.67 | Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. ( Citarella, F; Contegiacomo, A; d'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Iaffaioli, RV; Marinelli, A; Pagliarulo, C, 1986) |
| "One hundred thirty-one patients with operable breast cancer were treated with adjuvant chemoimmunotherapy consisting of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG)." | 3.66 | Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. ( Blumenschein, GR; Buzdar, AU; deAsis, DN; Samaan, NA, 1978) |
| "We used data from the International Breast Cancer Study Group (IBCSG) Trials V and VI." | 2.73 | Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. ( Castiglione-Gertsch, M; Gelber, RD; Gelber, S; Goldhirsch, A; Partridge, A; Winer, E, 2007) |
| "In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes." | 2.72 | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006) |
| "In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone." | 2.71 | Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ( Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Nasi, ML; O'Neill, A; Price, KN, 2003) |
| "Tamoxifen use was associated with elevated estradiol levels 1 year post-chemotherapy." | 1.40 | Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. ( Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH, 2014) |
| "Of examined 37 breast cancer patients (average age 42,3 +/- 1,2 years) 25 had not had any specific therapy by the date of investigation and the rest 12 had received in average 5,3 +/- 0,6 cycles of neoadjuvant chemotherapy mainly TAC and FAC." | 1.38 | [Decrease of testosterone level in blood of breast cancer patients of reproductive age after neoadjuvant chemotherapy]. ( Bershteĭn, LM; Boriakina, MP; Bozhok, AA; Poroshina, TE; Tsyrlina, EV, 2012) |
| "Tamoxifen use was a significant predictor for CIA (P = 0." | 1.36 | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. ( Chen, L; Dai, JC; Ling, LJ; Liu, XA; Ma, JJ; Tao, AD; Wang, S; Yin, H; Zha, XM; Zhou, WB, 2010) |
| "Treatment of breast cancer by combination therapy induced luteal insufficiency, anovulatory cycles and sometimes hypergonadotropic amenorrhea in premenopausal women with previously normal mentrual cycles and ovarian function." | 1.26 | The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer. ( Geiger, W; Künzig, HJ; Schmidt-Rhode, P; Schulz, KD; Weymar, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (35.85) | 18.7374 |
| 1990's | 9 (16.98) | 18.2507 |
| 2000's | 14 (26.42) | 29.6817 |
| 2010's | 11 (20.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sahin, T | 1 |
| Dizdar, O | 1 |
| Ozdemir, N | 1 |
| Zengin, N | 1 |
| Ates, O | 1 |
| Oksuzoglu, B | 1 |
| Sendur, MAN | 1 |
| Bilgin, B | 1 |
| Demir, M | 1 |
| Bozbulut, UB | 1 |
| Kilickap, S | 1 |
| Yalcin, S | 1 |
| Bershteĭn, LM | 1 |
| Boriakina, MP | 1 |
| Tsyrlina, EV | 1 |
| Poroshina, TE | 1 |
| Bozhok, AA | 1 |
| Cercek, A | 1 |
| Siegel, CL | 1 |
| Capanu, M | 1 |
| Reidy-Lagunes, D | 1 |
| Saltz, LB | 1 |
| Tiong, V | 1 |
| Rozita, AM | 1 |
| Taib, NA | 1 |
| Yip, CH | 1 |
| Ng, CH | 1 |
| Lambertini, M | 1 |
| Ceppi, M | 1 |
| Cognetti, F | 1 |
| Cavazzini, G | 1 |
| De Laurentiis, M | 1 |
| De Placido, S | 3 |
| Michelotti, A | 1 |
| Bisagni, G | 1 |
| Durando, A | 1 |
| Valle, E | 1 |
| Scotto, T | 1 |
| De Censi, A | 1 |
| Turletti, A | 1 |
| Benasso, M | 1 |
| Barni, S | 1 |
| Montemurro, F | 1 |
| Puglisi, F | 1 |
| Levaggi, A | 1 |
| Giraudi, S | 1 |
| Bighin, C | 1 |
| Bruzzi, P | 1 |
| Del Mastro, L | 4 |
| Han, HS | 2 |
| Ro, J | 2 |
| Lee, KS | 2 |
| Nam, BH | 1 |
| Seo, JA | 1 |
| Lee, DH | 1 |
| Lee, H | 2 |
| Lee, ES | 1 |
| Kang, HS | 2 |
| Kim, SW | 2 |
| Rosendahl, M | 1 |
| Ahlgren, J | 1 |
| Andersen, J | 1 |
| Bergh, J | 1 |
| Blomquist, C | 1 |
| Lidbrink, E | 1 |
| Lindman, H | 1 |
| Mouridsen, H | 1 |
| Bjerre, K | 1 |
| Andersson, M | 1 |
| Zhou, WB | 1 |
| Yin, H | 1 |
| Liu, XA | 1 |
| Zha, XM | 1 |
| Chen, L | 2 |
| Dai, JC | 1 |
| Tao, AD | 1 |
| Ma, JJ | 1 |
| Ling, LJ | 1 |
| Wang, S | 1 |
| Jung, M | 1 |
| Shin, HJ | 1 |
| Rha, SY | 1 |
| Jeung, HC | 1 |
| Hong, S | 1 |
| Moon, YW | 1 |
| Kim, HS | 1 |
| Oh, KJ | 1 |
| Yang, WI | 1 |
| Roh, JK | 1 |
| Chung, HC | 1 |
| Rodríguez-Lescure, A | 1 |
| Najafi, S | 1 |
| Djavid, GE | 1 |
| Mehrdad, N | 1 |
| Rajaii, E | 1 |
| Alavi, N | 1 |
| Olfatbakhsh, A | 1 |
| Najafi, M | 1 |
| Bahrami, A | 1 |
| Heidari, K | 1 |
| Munster, PN | 1 |
| Moore, AP | 1 |
| Ismail-Khan, R | 1 |
| Cox, CE | 1 |
| Lacevic, M | 1 |
| Gross-King, M | 1 |
| Xu, P | 1 |
| Carter, WB | 1 |
| Minton, SE | 1 |
| Park, IH | 1 |
| Lee, S | 1 |
| Jung, S | 1 |
| Jonat, W | 1 |
| Kaufmann, M | 1 |
| Sauerbrei, W | 2 |
| Blamey, R | 2 |
| Cuzick, J | 1 |
| Namer, M | 1 |
| Fogelman, I | 2 |
| de Haes, JC | 1 |
| de Matteis, A | 1 |
| Stewart, A | 2 |
| Eiermann, W | 1 |
| Szakolczai, I | 1 |
| Palmer, M | 2 |
| Schumacher, M | 2 |
| Geberth, M | 1 |
| Lisboa, B | 1 |
| Blake, GM | 1 |
| Serin, D | 2 |
| Wilpshaar, W | 1 |
| Castiglione-Gertsch, M | 3 |
| O'Neill, A | 2 |
| Price, KN | 2 |
| Goldhirsch, A | 4 |
| Coates, AS | 2 |
| Colleoni, M | 1 |
| Nasi, ML | 1 |
| Bonetti, M | 1 |
| Gelber, RD | 4 |
| Kumar, N | 1 |
| Allen, KA | 1 |
| Riccardi, D | 1 |
| Bercu, BB | 1 |
| Cantor, A | 1 |
| Minton, S | 1 |
| Balducci, L | 1 |
| Jacobsen, PB | 1 |
| Bonadonna, G | 4 |
| Moliterni, A | 1 |
| Zambetti, M | 1 |
| Daidone, MG | 1 |
| Pilotti, S | 1 |
| Gianni, L | 1 |
| Valagussa, P | 4 |
| Parulekar, WR | 1 |
| Day, AG | 1 |
| Ottaway, JA | 1 |
| Shepherd, LE | 1 |
| Trudeau, ME | 1 |
| Bramwell, V | 1 |
| Levine, M | 1 |
| Pritchard, KI | 1 |
| Roché, H | 2 |
| Kerbrat, P | 1 |
| Bonneterre, J | 1 |
| Fargeot, P | 1 |
| Fumoleau, P | 1 |
| Monnier, A | 1 |
| Clavère, P | 1 |
| Goudier, MJ | 1 |
| Chollet, P | 1 |
| Guastalla, JP | 1 |
| Bernhard, J | 1 |
| Zahrieh, D | 1 |
| Hürny, C | 1 |
| Forbes, JF | 1 |
| Murray, E | 1 |
| Collins, J | 2 |
| Aebi, S | 1 |
| Thürlimann, B | 2 |
| Partridge, A | 1 |
| Gelber, S | 1 |
| Winer, E | 1 |
| Berliere, M | 1 |
| Dalenc, F | 1 |
| Malingret, N | 1 |
| Vindevogel, A | 1 |
| Piette, P | 1 |
| Donnez, J | 1 |
| Symann, M | 1 |
| Kerger, J | 1 |
| Machiels, JP | 1 |
| Howell, A | 2 |
| Bush, H | 1 |
| George, WD | 1 |
| Howat, JM | 1 |
| Crowther, D | 1 |
| Sellwood, RA | 1 |
| Rubens, RD | 3 |
| Hayward, JL | 1 |
| Bulbrook, RD | 1 |
| Fentiman, IS | 1 |
| Rossi, A | 4 |
| Tancini, G | 2 |
| Bajetta, E | 2 |
| Marchini, S | 2 |
| Veronesi, U | 3 |
| Brambilla, C | 1 |
| Tesoro Tess, JD | 1 |
| Banfi, A | 2 |
| Costantini, M | 2 |
| Bianco, AR | 2 |
| Venturini, M | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 2 |
| Pagani, O | 1 |
| Castiglione, M | 1 |
| Rudenstam, CM | 1 |
| Lindtner, J | 1 |
| Crivellari, D | 1 |
| Coates, A | 1 |
| Cavalli, F | 1 |
| Simoncini, E | 1 |
| Fey, M | 1 |
| Price, K | 1 |
| Senn, HJ | 1 |
| Kailajärvi, M | 1 |
| Ahokoski, O | 1 |
| Virtanen, A | 1 |
| Salminen, E | 1 |
| Irjala, K | 1 |
| Vehmanen, L | 1 |
| Saarto, T | 1 |
| Elomaa, I | 1 |
| Mäkelä, P | 1 |
| Välimäki, M | 1 |
| Blomqvist, C | 1 |
| Samaan, NA | 1 |
| deAsis, DN | 1 |
| Buzdar, AU | 3 |
| Blumenschein, GR | 1 |
| Recchione, C | 1 |
| Schulz, KD | 1 |
| Schmidt-Rhode, P | 1 |
| Weymar, P | 1 |
| Künzig, HJ | 1 |
| Geiger, W | 1 |
| Koyama, H | 1 |
| Wada, T | 1 |
| Nishizawa, Y | 1 |
| Iwanaga, T | 1 |
| Aoki, Y | 1 |
| Toma, S | 1 |
| Repetto, L | 1 |
| Giacchero, A | 1 |
| Coialbu, T | 1 |
| Addamo, GF | 1 |
| Guido, T | 1 |
| Bhatavdekar, JM | 1 |
| Shah, NG | 1 |
| Patel, DD | 1 |
| Karelia, NH | 1 |
| Trivedi, SN | 1 |
| Vora, HH | 1 |
| Ghosh, N | 1 |
| Giri, DD | 1 |
| Balar, DB | 1 |
| Mehta, RR | 1 |
| Beattie, CW | 1 |
| Das Gupta, TK | 1 |
| Falliers, CJ | 1 |
| Gallo, C | 1 |
| Perrone, F | 1 |
| Matano, E | 1 |
| Pagliarulo, C | 2 |
| Sutton, R | 1 |
| Hortobagyi, GN | 2 |
| Tormey, DC | 1 |
| Brincker, H | 2 |
| Mouridsen, HT | 2 |
| Andersen, KW | 2 |
| Rose, C | 2 |
| Dombernowsky, P | 2 |
| Padmanabhan, N | 2 |
| Giai, M | 1 |
| De Fabiani, E | 1 |
| Lamberto, A | 1 |
| Cortese, P | 1 |
| Giardina, G | 1 |
| Rank, F | 1 |
| Jakobsen, A | 1 |
| Panduro, J | 1 |
| Beex, LV | 1 |
| Mackenzie, MA | 1 |
| Raemaekers, JM | 1 |
| Smals, AG | 1 |
| Benraad, TJ | 1 |
| Kloppenborg, PW | 1 |
| Marcus, CE | 1 |
| Smith, TL | 1 |
| Wang, DY | 1 |
| Moore, JW | 1 |
| Delrio, G | 1 |
| d'Istria, M | 1 |
| Fasano, S | 1 |
| Marinelli, A | 1 |
| Citarella, F | 1 |
| De Sio, L | 1 |
| Contegiacomo, A | 1 |
| Iaffaioli, RV | 1 |
| Dnistrian, AM | 1 |
| Greenberg, EJ | 1 |
| Dillon, HJ | 1 |
| Hakes, TB | 1 |
| Fracchia, AA | 1 |
| Schwartz, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.[NCT00711529] | Phase 3 | 27 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study[NCT00888082] | Phase 3 | 102 participants (Anticipated) | Interventional | Withdrawn | |||
| Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University[NCT00902720] | Phase 4 | 25 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All nine women who initiated hypnotherapy treatment completed the survey at the end of 8 weeks. One woman in the gabapentin arm did not submit a survey at 8 weeks. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 26 |
| Gabapentin | 22 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). Of 11 eligible women in the hypnotherapy arm, 2 never initiated treatment, and 3 did not complete the survey at this time point. Of the 14 eligible women in the gabapentin arm, 3 never initiated treatment, and 3 dropped out of the study before the 4 week time point. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 25.5 |
| Gabapentin | 21.5 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All women who were randomized were included in the baseline analysis (with the exception of 2 women excluded from the hypnotherapy arm who were deemed ineligible after randomization). (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 58 |
| Gabapentin | 45.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 10 |
| Gabapentin | 7.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 6.5 |
| Gabapentin | 4 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 1.5 |
| Gabapentin | 5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). A total of 15 diaries were submitted (7 hypnotherapy, 8 gabapentin). One person in each arm stopped recording in her diary before the 4 week mark." (NCT00711529)
Timeframe: Week 4
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 4 |
| Gabapentin | 4 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). Of the 13 women randomized to the hypnotherapy arm, 2 women were ineligible and therefore not included in analysis. Two women were unable to initiate treatment and did not submit diaries. An additional two women completed treatment but lost their diaries, leaving 7 diaries for analysis at baseline. Of the 14 randomized to receive gabapentin, 6 dropped out of the study and did not submit diaries." (NCT00711529)
Timeframe: Baseline
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 5 |
| Gabapentin | 4.5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). One woman in the hypnotherapy arm and 3 women in the gabapentin arm stopped keeping their diary before the 8 week mark." (NCT00711529)
Timeframe: Week 8
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 1 |
| Gabapentin | 3 |
2 reviews available for fluorouracil and Amenorrhea
| Article | Year |
|---|---|
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2005 |
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
Topics: Amenorrhea; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breas | 1997 |
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
Topics: Amenorrhea; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breas | 1997 |
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
Topics: Amenorrhea; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breas | 1997 |
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
Topics: Amenorrhea; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breas | 1997 |
21 trials available for fluorouracil and Amenorrhea
| Article | Year |
|---|---|
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2017 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.
Topics: Adult; Age Distribution; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Br | 2009 |
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2006 |
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2007 |
Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 2007 |
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1984 |
Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan.
Topics: Adult; Aged; Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response | 1980 |
Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Topics: Aged; Amenorrhea; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy | 1981 |
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Topics: Adult; Age Distribution; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 1998 |
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Amenorrhea; Antimetabolites; Antineoplastic Com | 2001 |
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Topics: Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Hormonal study in patients developing amenorrhea during adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1979 |
Castration induced by cytotoxic chemotherapy.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1989 |
A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1985 |
Mechanism of action of adjuvant chemotherapy in early breast cancer.
Topics: Adult; Age Factors; Aged; Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Combined Modality | 1986 |
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1987 |
Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.
Topics: Adult; Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breas | 1986 |
30 other studies available for fluorouracil and Amenorrhea
| Article | Year |
|---|---|
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta | 2019 |
[Decrease of testosterone level in blood of breast cancer patients of reproductive age after neoadjuvant chemotherapy].
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2012 |
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta | 2013 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplas | 2014 |
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2010 |
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Adjuvant chemotherapy in young women with breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Topics: Adult; Amenorrhea; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2011 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; C | 2012 |
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant | 2002 |
Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2004 |
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2005 |
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.
Topics: Adult; Amenorrhea; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2008 |
Adjuvant chemotherapy in breast cancer.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant | 1995 |
Alterations in laboratory test results during adjuvant breast cancer treatment.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Breast Neoplasms; | 2000 |
Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy.
Topics: Adult; Amenorrhea; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1978 |
The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; F | 1979 |
Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer.
Topics: Adult; Amenorrhea; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; Fluorouracil; Follicle Sti | 1977 |
Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients.
Topics: Adult; Amenorrhea; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1992 |
Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin | 1992 |
Endocrine profile in breast cancer patients receiving chemotherapy.
Topics: Adult; Age Factors; Amenorrhea; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Bre | 1992 |
Cancer chemotherapy: hormonal changes and recurring asthma.
Topics: Adenocarcinoma; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asthma; Breast Ne | 1991 |
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorou | 1991 |
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.
Topics: Abortion, Incomplete; Adolescent; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Ther | 1989 |
[Secondary effects of adjuvant therapy].
Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1985 |
Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1988 |
Ovarian function and adjuvant chemotherapy for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 1987 |
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1986 |
Chemohormonal therapy and endocrine function in breast cancer patients.
Topics: Adult; Amenorrhea; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 1985 |